Illumina, Inc. (ILMN)

Market Cap	18.63B
Revenue (ttm)	4.29B
Net Income (ttm)	703.00M
Shares Out	152.80M
EPS (ttm)	4.46
PE Ratio	27.33
Forward PE	25.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,125,800
Open	120.21
Previous Close	121.11
Day's Range	119.36 - 122.08
52-Week Range	68.70 - 155.99
Beta	1.45
Analysts	Hold
Price Target	114.93 (-5.72%)
Earnings Date	Oct 30, 2025

About ILMN

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 28, 2000
• Employees: 10,370
• Stock Exchange: NASDAQ
• Ticker Symbol: ILMN
• Website: https://www.illumina.com

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Analyst Summary

According to 15 analysts, the average rating for ILMN stock is "Hold." The 12-month stock price target is $114.93, which is a decrease of -5.72% from the latest price.

Price Target

$114.93

(-5.72% downside)

Analyst Consensus: Hold